The Pfizer Clinical Research Unit Brussels is conducting a study with a medical device containing 104 mg MPA (medroxyprogesterone acetate) in 0.65 mL suspension for injection and indicated for long-term female contraception via SC injection into the anterior thigh or abdomen every 13 weeks.

You are being invited to take part in a clinical study to evaluate an investigational medicinal product. An investigational medicinal product is a medicinal product that is still being studied to evaluate its efficacy, safety or mode of action.

Who may participate

This study is seeking healthy female participants.

Women of non-childbearing potential:
You may participate in this study provided that:

  • You are 18 or older, and
  • You have been surgically sterilised (hysterectomy or bilateral tubal ligation).

Women of childbearing potential:
At each visit to the PCRU, we will check that you are using the appropriate contraception.
You must fulfil one of the following conditions:

  • You have a non-hormonal IUD
  • You use a diaphragm
  • You use condoms
  • Your partner has undergone a vasectomy at least six months ago
  • You are abstinent from heterosexual intercourse as your preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.

These non-hormonal contraceptive methods will have to be started at least 14 days before the start of the study and will have to be continued until Day 150 of the study.

In addition to the criteria listed, participants must meet the following requirements:

  • Weight of 45 kg minimum
  • Body Mass Index of 17.5 - 50 kg/m2
  • Non-smoker, ex-smoker, smoker
  • Able to meet all study visit requirements There are other requirements for participation in this study. The study staff will explain these to you during the screening process.

Download the informed consent form




18 or older



Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

View more eligibility criteria

What to expect

The study is planned to last for approximately 7 months.
Several examinations or procedures will be required in connection with the study:
• A screening examination, during which you will sign the study ICD;
• 1 treatment visit on Day 1 and 21 ambulatory visits on Day 2, 4, 8, 11, 15, 18, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 113, 127 and 141.
• The follow up visit will take place on Day 150.


See if you may qualify

View study calendar

Long-term follow-up

a follow-up visit at the end of the study

How long is the study?

Approximately 7 months


Up to € 2.285, plus travel fees

Interested in participating?

Whether you are new to clinical research or already in our database, if you’d like to subscribe for this study, please use the PCRU Chatbot Charlie at the bottom right of the screen.


Interested in becoming our ambassador? 

The participants who are registered in the PCRU database can refer a friend or family member to screen for clinical trials on our site in Brussels. Read more information about our Ambassador Program here.